FDA Approves Frontline Eltrombopag for Severe Aplastic Anemia
The FDA has expanded the approval of eltrombopag in combination with standard immunosuppressive therapy to include newly diagnosed adult and pediatric patients 2 years and older with severe aplastic anemia.
Source: OncLive